MedTrace Logo

A Prospective Study Using SupraSDRM® in Promoting Healing and Reducing the Time to Grafting of Full-thickness Wounds

NCT06503406 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-02-21

No results posted yet for this study

Summary

This is a prospective, randomized, controlled, multi-center clinical study comparing SupraSDRM® to standard of care wound dressing, BTM, in the treatment of full-thickness wounds deemed not immediately suitable for definitive grafting will be performed.

Conditions

  • Surgical Wound
  • Burns
  • Trauma Injury

Interventions

DEVICE

SupraSDRM®

SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.

DEVICE

NovoSorb® BTM

NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140

Sponsors & Collaborators

  • The University of Texas Medical Branch, Galveston

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • The United States Army Institute of Surgical Research

    collaborator UNKNOWN

  • The Metis Foundation

    lead OTHER

Principal Investigators

  • Rodney Chan, MD · Metis Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-10-31
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503406 on ClinicalTrials.gov